A CANNABIS-BASED medicine has been approved for routine use on NHS Scotland for the first time, in a breakthrough for children with rare form of epilepsy.
Epidyolex has been approved by the Scottish Medicines Consortium to treat Dravet syndrome and Lennox Gastaut syndromes.
It has been recommended for use in England since November, but the SMC decision brings Scotland into line with the rest of the UK.
It also marks the first time that a cannabis-based medicine is being routinely funded on NHS Scotland.
Until now, a small number of patients were able to access the medication only through clinical trials or on compassionate grounds following case-by-case applications.
Dravet syndrome is a rare and severe form of epilepsy which begins in early childhood and is characterised by frequent and prolonged seizures. It is highly resistant to existing epilepsy medicines. Around two or three in…